R 56865 | CAS#104606-13-5 | anti-ischaemic

MedKoo Cat#: 461065 | Name: R 56865

Description:

WARNING: This product is for research use only, not for human or veterinary use.

R 56865 is an anti-ischaemic.

Chemical Structure

R 56865

CAS#104606-13-5

Theoretical Analysis

MedKoo Cat#: 461065

Name: R 56865

CAS#: 104606-13-5

Chemical Formula: C23H28FN3OS

Exact Mass: 413.1937

Molecular Weight: 413.55

Elemental Analysis: C, 66.80; H, 6.82; F, 4.59; N, 10.16; O, 3.87; S, 7.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

R 56865; R-56865; R56865;

IUPAC/Chemical Name

N-(1-(4-(4-fluorophenoxy)butyl)piperidin-4-yl)-N-methylbenzo[d]thiazol-2-amine

InChi Key

PZPXREFPAFDHNG-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H28FN3OS/c1-26(23-25-21-6-2-3-7-22(21)29-23)19-12-15-27(16-13-19)14-4-5-17-28-20-10-8-18(24)9-11-20/h2-3,6-11,19H,4-5,12-17H2,1H3

SMILES Code

CN(C1CCN(CCCCOC2=CC=C(F)C=C2)CC1)C3=NC4=CC=CC=C4S3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 413.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pijl AJ, Van Wezel HB, Koolen JJ, Piek JJ, Koch K, Swaan A, David GK, Visser CA, Van Zwieten PA. The negative inotropic and chronotropic effects of intravenous R 56865 during percutaneous transluminal coronary angioplasty. Br J Clin Pharmacol. 1995 May;39(5):531-5. PubMed PMID: 7669490; PubMed Central PMCID: PMC1365061. 2: Pijl AJ, Hendriks MG, Kam KL, Paffendorf M, van Zwieten PA. Effects of R 56865 on postischemic ventricular function in isolated rat working heart preparations obtained from healthy, diabetic and hypertensive animals. Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):619-26. PubMed PMID: 7969513. 3: Wermelskirchen D, Gleitz J, Urenjak J, Wilffert B, Tegtmeier F, Peters T. Flunarizine and R 56865 suppress veratridine-induced increase in oxygen consumption and uptake of 45Ca2+ in rat cortical synaptosomes. Neuropharmacology. 1992 Mar;31(3):235-41. PubMed PMID: 1630592. 4: Koch P, Schneider J, Fruh C, Wilhelm D, Wilffert B, Peters T. Interaction between R 56865 and alpha-adrenoceptors in the pithed rat. Arch Int Pharmacodyn Ther. 1989 May-Jun;299:134-43. PubMed PMID: 2570552. 5: Vollmer B, Meuter C, Janssen PA. R 56865 prevents electrical and mechanical signs of ouabain intoxication in guinea-pig papillary muscle. Eur J Pharmacol. 1987 Oct 6;142(1):137-40. PubMed PMID: 3691632. 6: Koch P, Wilhelm D, Wilffert B, Peters T. R 56865 differentiates between contractile agents with respect to the nifedipine-sensitive component in the isolated rat aorta. Pharmacology. 1989;39(1):11-8. PubMed PMID: 2555825. 7: Daniels MC, ter Keurs HE. Suppressive effects of R 56865 on triggered propagated contractions and triggered arrhythmias in rat cardiac trabeculae. J Cardiovasc Pharmacol. 1992 Aug;20(2):187-96. PubMed PMID: 1381009. 8: Damiano BP, Stump GL, Yagel SK. Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity. J Cardiovasc Pharmacol. 1991 Sep;18(3):415-28. PubMed PMID: 1720842. 9: Le Grand B, Coulombe A, John GW. Late sodium current inhibition in human isolated cardiomyocytes by R 56865. J Cardiovasc Pharmacol. 1998 May;31(5):800-4. PubMed PMID: 9593082. 10: Ichikawa H, Hearse DJ, Coetzee WA. Effects of R-56865 on transient inward current, Na(+)-Ca2+ exchange, and Ca2+ release from SR in cardiac myocytes. Am J Physiol. 1994 Feb;266(2 Pt 2):H511-20. Erratum in: Am J Physiol 1994 Aug;267(2 Pt 2):section H following table of contents. Am J Physiol 1994 Dec;267(6 Pt 3):section H followi. PubMed PMID: 8141352. 11: Heers C, Scheufler E, Wilhelm D, Wermelskirchen D, Wilffert B, Peters T. Differential effect of R 56865 on ouabain binding to isolated sarcolemma and intact atrial tissue of guinea-pig. Br J Pharmacol. 1991 Mar;102(3):675-8. PubMed PMID: 1364838; PubMed Central PMCID: PMC1917946. 12: Wilhelm D, Himmel H, Ravens U, Peters T. Characterization of the interaction of R 56865 with cardiac Na- and L-type Ca channels. Br J Pharmacol. 1991 Oct;104(2):483-9. PubMed PMID: 1665739; PubMed Central PMCID: PMC1908563. 13: Hartmann M, Decking UK. R 56865 exerts cardioprotective properties independent of the intracellular Na(+)-overload in the guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):160-5. Epub 2003 Sep 2. PubMed PMID: 14513202. 14: Tan HL, Netea AO, Sleeswijk ME, Mazón P, Coronel R, Opthof T, Janse MJ. R 56865 delays cellular electrical uncoupling in ischemic rabbit papillary muscle. J Mol Cell Cardiol. 1993 Sep;25(9):1059-66. PubMed PMID: 8283469. 15: Ver Donck L, Borgers M. Myocardial protection by R 56865: a new principle based on prevention of ion channel pathology. Am J Physiol. 1991 Dec;261(6 Pt 2):H1828-35. PubMed PMID: 1661091. 16: Koch P, Wilhelm D, Wermelskirchen D, Nebel U, Wilffert B, Peters T. Different effects of R 56865 and calcium entry blockers on K+- and noradrenaline-induced contractions and 45Ca uptake in rat aorta. Eur J Pharmacol. 1988 Dec 13;158(3):183-90. PubMed PMID: 3253097. 17: Verscheure Y, Pouget G, De Courtois F, Le Grand B, John GW. Attenuation by R 56865, a novel cytoprotective drug, of regional myocardial ischemia- and reperfusion-induced electrocardiographic disturbances in anesthetized rabbits. J Cardiovasc Pharmacol. 1995 Jan;25(1):126-33. PubMed PMID: 7723341. 18: Vogelgesang R, Scheufler E. R 56865 and flunarizine displace Ca2+ from phosphatidylserine monolayers in a stoichiometric manner. Eur J Pharmacol. 1990 Jan 23;188(1):17-22. PubMed PMID: 2307179. 19: Tegtmeier F, Wilhelm D, Frankow C, Thoné F, Vandeplassche L, Peters T. Effects of R 56865 and phenytoin on mechanical, biochemical, and morphologic changes during ouabain intoxication in isolated perfused rabbit heart. J Cardiovasc Pharmacol. 1992 Sep;20(3):421-8. PubMed PMID: 1279287. 20: Scheufler E, Urenjak J, Osikowska-Evers B, Beile A, Guttmann I, Wilffert B, Tegtmeier F, Peters T. Ouabain-induced changes of calcium and potassium in slices of hippocampus of the rat: comparison to hypoxia and effect of R 56865. Neuropharmacology. 1992 May;31(5):481-6. PubMed PMID: 1528398.